Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
3
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Disney+ offers sneak peek at 2025 lineup of Korean originals
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Teen smoking, drinking decline, while mental health, dietary habits worsen
-
10
Kia EV9 GT marks world debut at LA Motor Show
Drug Ministry cancels approval of 6 botulinum products
By Kan Hyeong-wooPublished : Dec. 2, 2021 - 18:32
The licenses of six botulinum drugs will be revoked on Dec. 13, the Ministry of Food and Drug Safety announced Thursday.
The Drug Ministry said the drugs were being sold in the country without obtaining the state approval to sell them in the domestic market.
The drugs are four of Hugel’s Botulax units and two of Pharma Research Bio’s ReNTox units.
The Drug Ministry will also shut down Pharma Research Bio’s production for six months, citing that the biopharmaceutical firm’s ReNTox units were exclusively approved for exports but they were sold in the country.
The ministry ordered both companies to recall and discard the cancelled drugs and asked medical institutions to cooperate in the recall process.
“We will do our best to crack down on and punish acts that threaten public health. We will guide and inspect the industry and provide safe medicines,” the ministry said in a press release.
The Drug Ministry said the drugs were being sold in the country without obtaining the state approval to sell them in the domestic market.
The drugs are four of Hugel’s Botulax units and two of Pharma Research Bio’s ReNTox units.
The Drug Ministry will also shut down Pharma Research Bio’s production for six months, citing that the biopharmaceutical firm’s ReNTox units were exclusively approved for exports but they were sold in the country.
The ministry ordered both companies to recall and discard the cancelled drugs and asked medical institutions to cooperate in the recall process.
“We will do our best to crack down on and punish acts that threaten public health. We will guide and inspect the industry and provide safe medicines,” the ministry said in a press release.
